<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5013">
  <stage>Registered</stage>
  <submitdate>1/06/2015</submitdate>
  <approvaldate>1/06/2015</approvaldate>
  <nctid>NCT02469467</nctid>
  <trial_identification>
    <studytitle>A Dose Escalation Study of VS-505 in End Stage Renal Disease Patients Undergoing Hemodialysis</studytitle>
    <scientifictitle>A Dose Escalation Study of VS-505 to Evaluate the Tolerability, Safety and Efficacy in End Stage Renal Disease Patients Undergoing Hemodialysis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>VDKDL001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>End Stage Renal Disease</healthcondition>
    <healthcondition>Hyperphosphatemia</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Kidney disease</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Other metabolic disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - VS-505

Experimental: VS-505 - 750 mg capsule


Other interventions: VS-505
VS-505 is orally administered with meal for 8 weeks

</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Inorganic phosphorus (Pi) change from baseline to end of treatment</outcome>
      <timepoint>8 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Calcium (Ca) change from baseline to end of treatment</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Ca x Pi change from baseline to end of treatment</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>intact parathyroid hormone change from baseline to end of treatment</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of patients whose Pi reduction is 0.65 mmol/L (2.0 mg/dL)</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Rate of patients whose Pi reaches the goal between 1.13 mmol/L (3.5 mg/dL) and 1.94 mmol/L (6.0 mg/dL)</outcome>
      <timepoint>8 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Written informed consent given

          -  Able to comply with the study procedures and medications

          -  On a stable hemodialysis (HD) regimen (3 times per week) including hemodialysis and
             hemodiafiltration for =12 weeks at screening and during the study period

          -  No change in prescribed dose or frequency of any of the following medications within 4
             weeks prior to screening

               1. Injectable iron agents

               2. Oral or injectable active vitamin D3

               3. Oral nutritional vitamin D

               4. Calcimimetics

               5. Calcium supplements

               6. Anti-osteoporotic medication including bisphosphonates

               7. Calcitonins

          -  Must be willing to avoid intentional changes in diet throughout the study

          -  Women of child-bearing potential or non-sterile male subjects and those who are
             sexually active with a non-sterile female partner must agree to use highly effective
             contraception

          -  Plasma Pi level &gt;1.94 mmol/L (6.0 mg/dL) to &lt;3.23 mmol/L (10.0 mg/dL) after 2 weeks
             washout will qualify patients to enter the treatment period</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Blood purification therapy other than HD (hemodialysis and hemodiafiltration)

          -  The plasma Pi level is &gt;2.26 mmol/L (7.0 mg/dL) within the latest three tests prior to
             screening.

          -  Variation of the plasma Pi is over 0.65 mmol/L (2.0 mg/dL) within the latest three
             tests prior to screening.

          -  Pre-emptive or scheduled renal transplant

          -  History of hemochromatosis or ferritin =1000 mcg/L

          -  Oral iron agents including prescribed and over-the-counter drugs at screening.

          -  Current clinically significant gastrointestinal (GI) disorder, including GI bleeding,
             colitis, inflammatory bowel disease, irritable bowel syndrome, chronic constipation,
             new diagnosis of peptic or duodenal ulcer disease, within 4 weeks prior to screening

          -  History of gastrectomy or duodenectomy, or GI tract surgery within 12 weeks prior to
             screening

          -  Hypertension: Defined using pre-dialysis vital of diastolic blood pressure &gt;110 mmHg
             or systolic blood pressure &gt;180 mmHg

          -  Possible parathyroid intervention including surgical parathyroidectomy and
             percutaneous ethanol injection therapy during the study period

          -  Clinical evidence of active malignancy and/or receiving systemic
             chemotherapy/radiotherapy with the exception of basal cell or squamous carcinoma of
             the skin

          -  Severe cardiovascular disorders such as recent myocardial infarction; unstable angina;
             congested heart failure (NYHA class II or above) hospitalized within 24 weeks (6
             months), valve stenosis, atrial fibrillation and arrhythmia

          -  History of event by cerebrovascular disease or cardiovascular disease within 24 weeks
             (6 months) prior to screening

          -  Active infection or current treatment with antibiotics within 2 weeks prior to
             screening

          -  History of HIV (ELISA and Western blot) test results

          -  Known active liver disease with aspartate aminotransferase or alanine aminotransferase
             levels greater than x3 the upper limit of normal

          -  Hepatitis B and/or hepatitis C treated with antiviral treatment within 4 weeks prior
             to screening

          -  History of allergy of VS-505 and its related components

          -  Receipt of any investigational drug within 4 weeks prior to screening

          -  Pregnant and breast-feeding women

          -  Other patients who in the opinion of the investigators are ineligible for the study</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>30</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/12/2016</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>LCR Clinical Research - Perth</hospital>
    <postcode> - Perth</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>KDL Inc.</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose is to evaluate the tolerability, safety and efficacy of VS-505 when given with
      meal for 8 weeks to hemodialysis patients with hyperphosphatemia</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02469467</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Johan Rosman, MD, Ph.D</name>
      <address>LCR Clinical Research</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>KDL inc</name>
      <address />
      <phone>+81-3-3234-3400</phone>
      <fax />
      <email>asao@kdl-japan.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>